Modalis Therapeutics Corporation (4883) Press Release
(Correction) Regarding Corrections to the "Consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]"
Earlier from Modalis Therapeutics
- Business Plans and Matters Related to Growth Potential
- Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
- Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
- Modalis Therapeutics - MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by the Food and Drug Administration